Venous Thromboembolic Risk of Estradiol Valerate–Dienogest Compared with Ethinyl Estradiol–Levonorgestrel Combined Oral Contraceptives
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This pooled analysis found a significantly decreased risk of venous thromboembolism for estradiol valerate-dienogest compared to ethinyl estradiol-levonorgestrel combined oral contraceptives.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
This pooled analysis compared the risk of venous thromboembolism (VTE) associated with combined oral contraceptives (COCs) containing estradiol (E2) valerate-dienogest with those containing ethinyl E2-levonorgestrel. Data were retrieved from two large, prospective, observational cohort studies. Propensity score subclassification was applied to balance baseline parameters between the COC user cohorts. Crude and adjusted hazard ratios (HRs) were calculated based on the extended Cox model. The pooled data set included 11,616 E2 valerate-dienogest users and 18,681 ethinyl E2-levonorgestrel users, contributing 17,932 and 29,140 women-years of observation, respectively. A significantly decreased VTE risk in E2 valerate-dienogest COCs compared with ethinyl E2-levonorgestrel COCs was observed (propensity score-stratified HR 0.46, 95% CI, 0.22-0.98). This pooled analysis expands data from a previous postauthorization safety study and provides valuable real-world safety information on the relative safety of current COCs.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Impact of estrogen type on cardiovascular safety of combined oral contraceptives 2016
- Efficacy and Safety of a Combined Oral Contraceptive Containing Estradiol Valerate/Dienogest: Results from a Clinical Study Conducted in North America 2013
- An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest 2012
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies 2021
Cited by (2)
References (10)
- An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest via openalex
- Efficacy and Safety of a Combined Oral Contraceptive Containing Estradiol Valerate/Dienogest: Results from a Clinical Study Conducted in North America via openalex
- Impact of estrogen type on cardiovascular safety of combined oral contraceptives via openalex
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies via openalex
- doi:10.1016/j.fertnstert.2016.09.027 via openalex
- doi:10.1093/biomet/70.1.41 via openalex
- W6681091350 via openalex
- doi:10.1093/ije/17.4.955 via openalex
- doi:10.1080/13625187.2019.1629412 via openalex
- doi:10.15761/fwh.1000178 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-13T18:33:16.088889+00:00
- unpaywall
- last seen: 2026-06-15T06:18:04.506796+00:00
License: CC0
· commercial use OK